[Antitubercular agents: pharmacogenetic factors in the development of adverse effects].
We studied the distribution of the acetylator phenotype in 47 patients aged 15 to 77 years receiving isonyazid as antituberculous therapy. 62% were fast and 32% slow acetylators. Ethnical, socio-economic and biologic factors were not related to acetylator type. The incidence of liver alterations, mainly elevated transaminase levels, was higher than reported in the literature and was not shown to be influenced by acetylator type. Adverse reactions to isonyacid were not related to drug serum levels.
Ligueros
M
M
Departamento de Farmacología, Facultad de Medicina, Universidad de Chile, Santiago.
Saavedra
H
H
Neira
S
S
Cruz-Coke
R
R
Saavedra
A
A
Kramer
V
V
Gelman
M
M
Nuñez
A
A
Prieto
J C
JC
D000107:Acetylation; D000123:Acetyltransferases / Q000235:genetics / Q000378:metabolism*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000235:genetics / Q000378:metabolism; D000995:Antitubercular Agents / Q000009:adverse effects* / Q000378:metabolism; D001219:Aspartate Aminotransferases / Q000235:genetics / Q000378:metabolism; D002677:Chile; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011446:Prospective Studies
D000995:Antitubercular Agents; D000123:Acetyltransferases; D001219:Aspartate Aminotransferases; D000469:Alkaline Phosphatase; D007538:Isoniazid
Medicamentos antituberculosos: influencias farmacogeneticas en el desarrollo de reacciones adversas.